Bio

Christopher Haynes is the Director of Industry and Technology Transactions within the Industrial Contracts Office, Office of Technology Licensing. In this capacity, Chris is responsible for the oversight of daily activities of the Industrial Contracts Office. Chris has extensive experience drafting and negotiating complex agreements and interfacing with research staff to ensure research objectives are met. Prior to joining Stanford, Chris's career has spanned both pharmaceutical and academic settings. His career experience includes previously roles as Senior Counsel - Licensing and Transactions at Sangamo Therapeutics, Inc., In-House Counsel - Worldwide Research and Discovery (WWRD) and Business Development (BD) at BioMarin Pharmaceutical, Inc., and Commercialization Manager and IP Counsel at the University of Louisville's Office of Technology Transfer.

Education & Certifications

  • Ph.D., University of Louisville, Pharmacology & Toxicology (2014)
  • M.S., University of Louisville, Pharmacology & Toxicology (2011)
  • J.D., University of Louisville, Law (2002)
  • Bachelor's, University of Louisville, Biology (1998)

Contact

  • Work
    clhaynes@stanford.edu
    University - Staff Department: Office of Technology Licensing (OTL) Position: Director of Industry and Technology Transactions
    • 415 BROADWAY
    • REDWOOD CITY,  California  94063 

Additional Info

  • Mail Code: 8854

Professional Affiliations and Activities

  • Licensed Attorney, Kentucky Bar Association (2002 - Present)
  • Licensed Patent Attorney, United States Patent and Trademark Office (2001 - Present)

All Publications

  • Pharmacokinetics of the Antiviral Lectin Griffithsin Administered by Different Routes Indicates Multiple Potential Uses. Viruses Barton, C., Kouokam, J. C., Hurst, H., Palmer, K. E. 2016; 8 (12)

    Abstract

    Griffithsin (GRFT) is a red alga-derived lectin with demonstrated broad spectrum antiviral activity against enveloped viruses, including severe acute respiratory syndrome-Coronavirus (SARS-CoV), Japanese encephalitis virus (JEV), hepatitis C virus (HCV), and herpes simplex virus-2 (HSV-2). However, its pharmacokinetic profile remains largely undefined. Here, Sprague Dawley rats were administered a single dose of GRFT at 10 or 20 mg/kg by intravenous, oral, and subcutaneous routes, respectively, and serum GRFT levels were measured at select time points. In addition, the potential for systemic accumulation after oral dosing was assessed in rats after 10 daily treatments with GRFT (20 or 40 mg/kg). We found that parenterally-administered GRFT in rats displayed a complex elimination profile, which varied according to administration routes. However, GRFT was not orally bioavailable, even after chronic treatment. Nonetheless, active GRFT capable of neutralizing HIV-Env pseudoviruses was detected in rat fecal extracts after chronic oral dosing. These findings support further evaluation of GRFT for pre-exposure prophylaxis against emerging epidemics for which specific therapeutics are not available, including systemic and enteric infections caused by susceptible enveloped viruses. In addition, GRFT should be considered for antiviral therapy and the prevention of rectal transmission of HIV-1 and other susceptible viruses.

    View details for DOI 10.3390/v8120331

    View details for PubMedID 27999325

    View details for PubMedCentralID PMC5192392

  • Activity of and effect of subcutaneous treatment with the broad-spectrum antiviral lectin griffithsin in two laboratory rodent models. Antimicrobial agents and chemotherapy Barton, C., Kouokam, J. C., Lasnik, A. B., Foreman, O., Cambon, A., Brock, G., Montefiori, D. C., Vojdani, F., McCormick, A. A., O'Keefe, B. R., Palmer, K. E. 2014; 58 (1): 120-7

    Abstract

    Griffithsin (GRFT) is a red-alga-derived lectin that binds the terminal mannose residues of N-linked glycans found on the surface of human immunodeficiency virus type 1 (HIV-1), HIV-2, and other enveloped viruses, including hepatitis C virus (HCV), severe acute respiratory syndrome coronavirus (SARS-CoV), and Ebola virus. GRFT displays no human T-cell mitogenic activity and does not induce production of proinflammatory cytokines in treated human cell lines. However, despite the growing evidence showing the broad-spectrum nanomolar or better antiviral activity of GRFT, no study has reported a comprehensive assessment of GRFT safety as a potential systemic antiviral treatment. The results presented in this work show that minimal toxicity was induced by a range of single and repeated daily subcutaneous doses of GRFT in two rodent species, although we noted treatment-associated increases in spleen and liver mass suggestive of an antidrug immune response. The drug is systemically distributed, accumulating to high levels in the serum and plasma after subcutaneous delivery. Further, we showed that serum from GRFT-treated animals retained antiviral activity against HIV-1-enveloped pseudoviruses in a cell-based neutralization assay. Overall, our data presented here show that GRFT accumulates to relevant therapeutic concentrations which are tolerated with minimal toxicity. These studies support further development of GRFT as a systemic antiviral therapeutic agent against enveloped viruses, although deimmunizing the molecule may be necessary if it is to be used in long-term treatment of chronic viral infections.

    View details for DOI 10.1128/AAC.01407-13

    View details for PubMedID 24145548

    View details for PubMedCentralID PMC3910741